Go to main content

R&D Story

GC Pharma’s researchers
Continue to rise
To the challenge of saving lives.

Third-Generation recombinant factor VIII Treatment for Hemophilia

GreenGene F

With GreenGene F, GC Pharma became third in the world to successfully develop a third-generation recombinant protein drug for hemophilia-A. As such, the product epitomizes the company’s technological innovation and expertise. Having been approved for Phase 3 clinical trials, the drug is currently under drug approval process in China, a market with a huge potential for growth. By continuing to research and develop next-generation long acting hemophilia treatments, GC Pharma will expand its presence in the North American and European markets as well and increase its share of the global market.

A representative photograph of developing a professional medicine.

World-Class Quality

Plasma Derivatives

GC Pharma remains committed to improving the products that have already won government and market approval, continuing to improve quality and diversifying dosages and types. IVIG-SN, human normal immunoglobulin for immunodeficiency, has obtained approval in 15 countries worldwide and is enjoying growing demand in South America and elsewhere. Currently under Phase 3 clinical trial in the United States, the product is expected to be launched on the American market in a few years.

A Pioneer in the Global Vaccine Market


GC Pharma was third in the world to develop its own hepatitis-B vaccine (Hepavax-B, approved by the Korean government in 1983). The company was also first in the world to develop a vaccine against hemorrhagic fever with renal syndrome, known as Hantavax (approved in 1990). It was, moreover, second in the world to develop a chickenpox vaccine, which it named Suduvax (approved in 1993). These and subsequent vaccine products have helped GC Pharma consolidate its reputation as a leading vaccine manufacturer. The company’s GCFLU (trivalent seasonal flu vaccine; approved in 2009), Green Flu-S (vaccine against H1N1 flu, approved in 2009) and Green Flu-S Plus (added with immune-boosting properties, approved in 2010) also helped to safeguard the Korean public against the worldwide H1N1 epidemic in 2009.

GC Pharma’s trivalent flu vaccine, the first-ever to be developed in Asia, became the fourth flu vaccine in the world to pass the World Health Organization (WHO)’s prequalification, necessary for participation in international bids. GCFLU Quadrivalent (approved in Korea in 2015), which has further expanded the range of flu viruses against which the public can be vaccinated, was also the second quadrivalent flu vaccine to win WHO prequalification. Furthermore, GC Pharma became the first company in Korea to launch a tetanus-diphtheria (Td) vaccine (approved in 2016). The company currently focuses on developing a new mixed vaccine (Tdap) that can protect the public against tetanus, diphtheria, and pertussis all in one. Having secured a vaccine pipeline against a variety of diseases, GC Pharma continues to improve its vaccines in light of international standards in an effort to increase their shares of the global market.

Oncology, Immunology, and Cell Therapy

GC Pharma succeeded in developing Neulapeg, a treatment for neutropenia, in 2014. Designed as a supplement for immunosuppressant chemotherapy and thereby minimizing the treatment’s side effects, Neulapeg offers a longer half-life than its first-generation product. It has also enabled the Korean medical community to cease importing similar drugs from overseas. In addition, GC Pharma is working on introducing an innovative antibody production technology. The company continues to research and develop new candidate materials for immunotherapy for cancer patients. Its specialized subsidiaries are also helping the company strengthen its position in cell therapy, which is emerging as a new potential source of economic growth.

Restoring Hope to People
with Rare Diseases

Rare Disease Treatments

At GC Pharma, we believe it our duty to research and develop treatments for rare diseases, which are difficult to make and enjoy little market prospect, but which are crucial to saving lives. The first success in this regard came in the form of Hunterase, a treatment for Hunter syndrome, a hereditary metabolic disorder also known as mucopolysaccharidosis (MPS) type-II, in 2012. As the second Hunter syndrome treatment to be developed in the world, Hunterase has helped to lighten the financial burden on Korean patients and families by replacing the expensive imported alternative, and significantly improved quality of life for patients. Under GC Pharma’s plan to bring this innovative drug to Hunter syndrome patients around the world, it has been introduced into eight South American and North African markets. Recently NDA was submitted in China, and it is currently under clinical trials in many countries as well.

A representative photograph of developing a professional medicine.

Future Strategy

GC Pharma has been accumulating expertise in plasma derivatives, vaccines, and recombinant proteins. In the process, the company has made significant impact on treatment for patients and on public health. GC Pharma is now ready to maximize and upgrade the values of its existing products, and engage in strategic R&D activities to further strengthen its pipeline of products against a wider range of diseases.


GC녹십자는 이메일 수집을 거부합니다

본 웹사이트에 게시된 이메일 주소가 전자우편 수집 프로그램이나
그 밖의 기술적 장치를 이용하여 무단으로 이메일 주소를 수집하는 행위를 거부하며,
이를 위반시 정보통신망 이용촉진 및 정보보호 등에 관한 법률에 의해 형사처벌됨을
유념하시기 바랍니다

게시일: 2003년 9월 1일